These findings suggest that while RPLAR cancer hotspot mutants generally have a less pronounced effect on p53 transactivation compared to other cancer-associated p53 mutations, specific RPLAR mutations can still significantly impair or enhance transactivation. The gene discussed is TP53; the disease is cancer.